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Transforming growth factor 1 genotype polymorphisms
determine AV fistula patency in hemodialysis patients
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Transforming growth factor 1 genotype polymorphisms de-
termine AV fistula patency in hemodialysis patients.
Background. In hemodialysis patients with an arteriovenous
(AV) fistula, access failure is primarily due to fistula stenosis,
which predisposes to thrombosis and subsequent access loss.
The risk for access failure differs interindividually, an observa-
tion that is independent from vascular anatomy in a significant
number of patients. Fistula stenosis is histologically character-
ized by intimal hyperplasia, which is induced by growth factors,
among which transforming growth factor 1 (TGF-1) is of
major importance. The quantitative production of TGF-1 inter-
individually differs due to polymorphisms in the gene region
encoding the signal sequence of the cytokine. We hypothesized
that the TGF-1 genotype, by influencing the development of
arteriovenous fistula stenosis, determines the risk for vascular
access failure.
Methods. One hundred twenty patients who had undergone
placement of an AV fistula for initiation of hemodialysis treat-
ment were genotyped for the polymorphic bases at position
869 and 915 of the TGF-1 gene. The primary end-point
was time from fistula placement to access failure.
Results. AV fistula patency was significantly associated with
the TGF-1 genotype (P  0.0046); patency was 62.4% and
81.2% after 12 months for TGF-1 high and intermediate pro-
ducers, respectively. In contrast, AV fistula patency neither
differed between diabetic and nondiabetic patients, nor between
patients with and without manifest cardiovascular disease.
Conclusion. Polymorphisms in the gene region encoding the
signal sequence of TGF-1 influence the risk for hemodialysis
access failure. By inducing synthesis of extracellular matrix
proteins, overproduction of TGF-1 may accelerate the devel-
opment of intimal hyperplasia, resulting in fistula stenosis and
subsequent access failure.
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Vascular access complications substantially contribute
to morbidity and hospitalization in hemodialysis patients.
They account for 16 to 20% of dialysis patient hospital-
izations in the United States [1] at a cost of $1 billion
annually [2].
The major complications of permanent vascular access
are arteriovenous (AV) fistula stenoses and vascular ac-
cess infections. AV fistula stenoses account for over 80%
of AV access thromboses [3, 4]; AV access thromboses
are responsible for 80 to 85% of AV access failures. The
surgical technique of fistula anastomosis and the regular
care and puncture techniques are well-known factors
that influence fistula patency. However, a large interindi-
vidual difference in the likelihood of developing stenoses
remains unexplained. Thus, the prospective identifica-
tion of patients who are prone to early stenosis would be
of high clinical importance. These patients might benefit
from a prophylactic medication inhibiting the develop-
ment of AV fistula stenoses.
AV access stenosis is histologically characterized as
intimal hyperplasia [5–8]; vascular smooth muscle cells
(VSMC) initially proliferate in the media, and then mi-
grate from the media to the intima, where they finally
induce intimal expansion via exuberant synthesis of ex-
tracellular matrix [9]. VSMC proliferation, migration,
and extracellular matrix synthesis are mediated by sev-
eral growth factors, among which transforming growth
factor 1 (TGF-1) and platelet-derived growth factor
(PDGF) are of major importance [9]. The synthesis of
TGF-1 interindividually differs due to polymorphisms
in the gene region encoding the signal sequence of the
cytokine [10]. We hypothesized that hemodialysis pa-
tients with a TGF-1 high-producer genotype are prone
to earlier fistula stenosis and subsequent access failure.
METHODS
Patients
We identified all patients from two institutions (De-
partment of Nephrology, University Homburg, Germany,
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and Zentrum fu¨r Heimdialyse, Homburg, Germany) who
were treated for end-stage renal disease between January
1998 and December 2001, for whom complete clinical
information could be recovered from the files and for
whom blood samples for genotyping were available. Pa-
tients were included in our study if a wrist (radial-cephal-
ic) or elbow (brachial-cephalic or brachial-basilic) pri-
mary AV fistula was created as first vascular access for
hemodialysis treatment between January 1, 1984 and
December 31, 2001, excluding patients with an AV graft
of synthetic material. The primary end point was time
from fistula placement to the first episode of access fail-
ure (unassisted patency). Access failure was determined
on the basis of medical charts of our institution, in which
all fistula interventions are recorded, as well as by re-
peated standardized interviews of the patients by a single
investigator (G.H.H.). Access failure was defined as the
need for any angioplastic or surgical intervention to cor-
rect or replace a poorly or nonfunctioning fistula, which
occurred at least 8 weeks after fistula placement.
Any access failure within the first 8 weeks after fistula
placement was considered related to insufficient fistula
dilation rather than to intimal hyperplasia. Thus, in pa-
tients in whom access failure occurred within 8 weeks
after fistula placement, and in whom a new AV fistula
had to be created, this second AV fistula was subse-
quently analyzed, and unassisted patency was defined as
time from placement of the second AV fistula to access
failure, as defined above.
Patients were censored at the time of hemodialysis
therapy discontinuation for recovery of renal function
(more than 3 months without need for renal replacement
therapy, N  2), renal transplantation (N  13), death
due to a functioning access (N  4), or loss to follow-
up (N  3). No study patient switched to peritoneal
dialysis. The observation period was terminated on
March 1, 2002.
Patients were excluded if the first episode of access
failure was not due to stenosis-related events defined
as angioplastic or surgical interventions because of AV
fistula aneurysm, steal syndrome, or infection.
Comorbidity was assessed by chart review. Coronary
artery disease was diagnosed in patients who had either
had a myocardial infarction or who had undergone coro-
nary artery bypass surgery or coronary artery angioplasty
at any time before the first episode of AV fistula failure
or before censoring. In patients who had had a stroke
or had undergone carotic endarterectomy or carotic an-
gioplasty, cerebrovascular disease was diagnosed. Fi-
nally, in patients who had undergone peripheral bypass
surgery, nontraumatic lower extremity amputation, or
lower limb artery angioplasty, peripheral artery disease
was diagnosed. Patients were defined as having cardio-
vascular disease if they had coronary artery disease,
cerebrovascular disease, or peripheral artery disease.
We recruited 64 healthy Caucasian men (N  34) and
women (N  30) without kidney disease to be control
patients. Informed consent was obtained from all pa-
tients and controls, and genotyping studies were ap-
proved by the local ethics committee.
TGF-1 genotyping
We analyzed 2 single nucleotide polymorphisms in
the DNA sequence encoding the signal sequence of the
TGF-1 protein, located at position 869 (codon 10,
TC, leucinproline) and position 915 (codon 25,
GC, arginineproline). Both single-base substitutions
result in different levels of TGF-1 production. According
to Perrey et al [11], 3 different cytokine-producer types
are distinguished: high-producer haplotypes are TC (co-
don 10)/GG (codon 25) and TT/GG; intermediate-pro-
ducer haplotypes are CC/GG, TC/GC, and TT/GC; and
low-producer haplotypes are CC/CC, CC/GC, TT/CC,
and TC/CC, respectively. Genomic DNA was isolated
from anticoagulated venous blood samples using the
QIAamp DNA isolation kit (Qiagen, Hilden, Germany).
TGF-1 genotyping was performed using the amplifica-
tion refractory mutation system (ARMS)-polymerase
chain reaction (PCR) methodology, as described by Per-
rey et al [12].
Briefly, 50 to 100 ng DNA were amplified in a final
volume of 25 L containing 2.5 mmol MgCl2 (Qiagen),
1 reaction buffer (Qiagen), 200 mol each desoxy-
nucleoside triphosphate (dNTP) (Roche Applied Sci-
ence, Mannheim, Germany), 1 Solution Q (Qiagen),
5 mol of each primer, and 1 U HotStar Taq polymerase
(Qiagen). The protocol for the PCR Express Thermal
Cycler (Hybaid, Heidelberg, Germany) was as follows:
15 minutes at 95C, 10 cycles of 20 seconds at 95C, 50
seconds at 65C, 50 seconds at 72C, 24 cycles of 20
seconds at 95C, 50 seconds at 59C, 50 seconds at 72C,
and 7 minutes at 72C. The amplified products (PCR
product size of TGF-1 codon 10, 241 bp; codon 25,
233 bp) were fractionated electrophoretically on a 2%
agarose gel and visualized by ethidium bromide staining
(0.5 mg/mL) and ultraviolet light detection. All typing
analysis contained negative and positive controls.
Statistics
Data management and statistical analysis were done
using the Prism statistical software (version 3.03; Graph-
pad, San Diego, CA, USA). Frequency counts were com-
pared by chi-square analysis. Continuous data are re-
ported as mean  standard deviation and compared
using the Kruskal-Wallis test. The distribution of geno-
type frequencies in patients and control were compared
using a chi-square analysis. Survival curves were calcu-
lated by the Kaplan-Meier method and compared by the
log-rank test. In addition, for comparison of 2 survival
curves, the hazard ratio and its 95% confidence interval
were calculated.
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Table 1. Transforming growth factor 1 (TGF-1) signal sequence polymorphic allele frequencies
Patients Controls Patients Controls
Genotype N N Cytokine-producer type N N
CC/CC 1 0 TGF-1 low producer 5 4
CC/GC 4 4
CC/GG 20 7 TGF-1 intermediate producer 34 13
TC/GC 11 5
TT/GC 3 1
TC/GG 34 18 TGF-1 high producer 81 47
TT/GG 47 29
The first two characters indicate the bases at position 869 (codon 10); the following two characters give the bases at position 915 (codon 25) of the signal
sequence. The low producer genotypes TT/CC and TC/CC were found neither among the hemodialysis patients nor among control patients.
Table 2. Demographic characteristics, primary renal diseases, and comorbidity
TGF-1 producer type
Total High Intermediate Low
N  120 N  81 N  34 N  5 P
Mean age 57.114.4 57.214.8 56.114.3 62.67.2 0.70
Male/female 70/50 47/34 19/15 4/1 0.59
Elbow/wrist fistula 18/102 12/69 5/29 1/4 0.95
Primary renal disease
Diabetic nephropathy 39 (32.5%) 24 (29.6%) 12 (35.3%) 3 (60%) 0.86
Glomerulonephritis 20 (16.7%) 15 (18.5%) 5 (14.7%) 0 (0%)
Autosomal-dominant polycystic renal disease 14 (11.7%) 11 (13.6%) 2 (5.9%) 1 (20%)
Pyelonephritis 7 (5.8%) 6 (7.4%) 1 (2.9%) 0 (0%)
Nephrosclerosis 7 (5.8%) 5 (6.2%) 2 (5.9%) 0 (0%)
Other/unknown primary renal disease 33 (27.5%) 20 (24.7%) 12 (35.5%) 1 (20.0%)
Comorbidity
Coronary artery disease 23 (19.2%) 17 (21.0%) 5 (14.7%) 1 (20.0%) 0.74
Cerebrovascular disease 9 (7.5%) 7 (8.6%) 2 (5.9%) 0 (0.0%) 0.71
Peripheral artery disease 12 (10.0%) 5 (6.2%) 6 (17.6%) 1 (20.0%) 0.13
Diabetes mellitus 46 (38.3%) 28 (34.6%) 15 (44.1%) 3 (60%) 0.38
RESULTS
Patient characteristics
One hundred twenty patients met the inclusion criteria
and were enrolled in the study. Table 1 shows the fre-
quencies of the two single-nucleotide polymorphisms in
the DNA encoding the signal sequence of the TGF-1
protein at positions 869 (codon 10) and 915 (codon
25). According to their genotype, 81 patients were classi-
fied as TGF-1 high producers, 34 patients were interme-
diate producers, and 5 patients were low producers,
respectively. The genotype distributions for the 2 poly-
morphisms did not differ between patients and healthy
controls (Table 1).
TGF-1 high producers, intermediate producers, and
low producers were further characterized according to
demographic data, primary renal diseases, and comor-
bidity (Table 2). The 3 groups did not significantly differ
with respect to age, gender, location of AV fistula (wrist
vs. elbow), primary renal disease, and the presence of
coronary artery disease, cerebrovascular disease, or pe-
ripheral artery disease. All patients were of Caucasian
ethnicity, with the exception of 1 patient in the TGF-1
high producer group who was of African ethnicity.
Relationship between the TGF-1 phenotype and AV
fistula patency
Among the 81 patients who were TGF-1 high produc-
ers, 50 patients developed AV fistula failure after a mean
time of 13.6  13.5 months. The remaining 31 patients
who had no fistula failure until censoring were followed
for 36.0  25.8 months.
Within the 34 TGF-1 intermediate producers, 9 pa-
tients had fistula failure that occurred after 10.8  7.9
months. The 25 patients who had no fistula failure had
a mean follow-up of 31.7 24.8 months. Time of follow-
up in patients without fistula failure did not significantly
differ between TGF-1 high and intermediate producers.
Of the 5 patients who were TGF-1 low producers,
fistula failure occurred in 2 patients after 5 and 18
months, respectively, whereas 3 patients were censored
after 4, 14, and 23 months with functioning AV fistulas.
Because the number of TGF-1 low producers was too
low to allow for a valid statistical comparison to interme-
diate and high TGF-1 producers, these 5 patients were
excluded from the analysis of fistula patency stratified
from TGF-1 producer type. However, inclusion of
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Fig. 1. Kaplan-Meier analysis of arteriovenous (AV) fistula patency
stratified by transforming growth factor 1 (TGF-1) producer type.
By log-rank test, AV fistula patency was significantly better for TGF-1
intermediate producers (solid line) compared to TGF-1 high producers
(dotted line); P  0.0046. TGF-1 low producers were too low in
number to allow a valid statistical comparison to intermediate and high
producers.
TGF-1 low producers did not significantly change re-
sults of fistula survival analysis.
As depicted in Figure 1, AV fistula patency differed
significantly when patients were classified according to
their TGF-1 phenotype. Fistula patency was 62.4% and
81.2% for TGF-1 high and intermediate producers after
12 months, respectively; after 24 months, it was 48.1%
and 66.7%, respectively (P  0.0046; hazard ratio, 2.63
[1.28 to 3.90] for high producers compared to intermedi-
ate producers).
Relationship between demographic characteristics and
AV fistula patency
There was no difference in AV fistula patency between
male and female patients; the hazard ratio for access
failure was 1.00 (0.60 to 1.69) for female patients com-
pared to male patients. When classifying the study group
according to their age, patients who were at least 65
years of age when the fistula was created tended to have
earlier AV fistula failure, although differences were not
significant (P  0.10) (Fig. 2).
Relationship between comorbidity and
AV fistula patency
AV fistula patency did not differ in the 39 patients who
had end-stage renal disease due to diabetic nephropathy
compared to the 81 patients who had any other primary
renal disease (P  0.30) (Fig. 3). Twelve months after
fistula placement, patency was 62.6% and 70.9% for pa-
tients with and without diabetic nephropathy, respec-
tively. The hazard ratio for access failure was 1.31 (0.77
to 2.35) for patients with diabetic nephropathy compared
to those with any other primary renal disease.
Fig. 2. Kaplan-Meier analysis of arteriovenous (AV) fistula patency
stratified by age. By log-rank test, AV fistula patency did not differ
significantly between patients who were younger than 50 years of age
(dotted line), 50 to 64 years of age (dashed line), and 65 years of age
and older (solid line), respectively. P  0.10.
Fig. 3. Kaplan-Meier analysis of arteriovenous (AV) fistula patency
stratified by primary renal disease. By log-rank test, AV fistula patency
did not differ significantly between patients with diabetic nephropathy
(dotted line) and patients with any other primary renal disease (solid
line). P  0.30.
When comparing all patients with diabetes mellitus
(patients who had diabetic nephropathy and those who
had any other primary renal disease, but who were diag-
nosed as having diabetes mellitus as a comorbidity; N 
46) to nondiabetic patients (N  74), the hazard ratio
for access failure was 1.46 (0.88 to 2.62) for diabetic
patients.
Patients with cardiovascular disease did not develop
fistula failure earlier than patients without cardiovascu-
lar disease [12 months’ patency, 72.9% and 66.0%, re-
spectively; hazard ratio 0.99 (0.88 to 2.17) for patients
with cardiovascular disease] (Fig. 4).
Moreover, there was no significant difference in fistula
patency between patients with an elbow fistula and those
with a wrist fistula (data not shown).
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Fig. 4. Kaplan-Meier analysis of arteriovenous (AV) fistula patency
stratified by comorbidity. By log-rank test, AV fistula patency did not
differ significantly between patients with cardiovascular disease (dotted
line) and patients without cardiovascular disease (solid line). P  1.00.
DISCUSSION
Hemodialysis treatment requires a well-functioning
vascular access. Current Disease Outcomes Quality Ini-
tiative (DOQI) guidelines recommend wrist (radial-
cephalic) and elbow (brachial-cephalic) primary AV fis-
tulas as the preferred type of access [13] because of lower
complication rates and lower morbidity associated with
their creation compared to other access options. In pri-
mary AV fistulas, stenosis is the most important func-
tional defect, resulting from intimal hyperplasia [5–8]
with VSMC proliferation, migration, and extracellular
matrix synthesis [9]. AV fistula stenosis reduces dialysis
quality via a decrease in fistula blood flow, and it predis-
poses to thrombosis and subsequent access failure. The
likelihood of AV fistula stenosis differs interindividually;
however, risk factors contributing to vascular access
complications are only partly defined [14].
TGF-1 is a multifunctional cytokine that is implicated
in the regulation of proliferation and differentiation of
many cell types [15]. It exerts its effect by binding to cell-
surface receptors, three of which have been identified in
a variety of cells, including VSMC.
Physiologically, TGF-1 is among the key cytokines
that play a role in the initiation and termination of wound
healing after tissue injury [16]. Pathologically, increases
or decreases in the expression of TGF-1 have been
linked to numerous diseases—in fibrotic disease of the
kidney, liver, and lung, overproduction of TGF-1 re-
sults in excessive deposition of extracellular matrix
[15, 16]. In contrast, a decreased TGF-1 expression has
been linked to atherosclerosis [17], as TGF-1 inhibits
migration and proliferation of macrophages and protects
endothelial function [18, 19].
Polymorphisms in the gene for TGF-1 determine the
production of TGF-1 [10] and can predict the suscepti-
bility to certain diseases. Polymorphisms that result in
increased TGF-1 production are linked to fibrotic lung
disease [10] and arterial hypertension [20, 21]. Polymor-
phisms leading to decreased TGF-1 predispose to myo-
cardial infarction [20] and atopic dermatitis [22]. TGF-1
expression is increased in the luminal and abluminal
neointima of stenosed AV fistulas and correlates to neo-
intimal cell number [8, 23–25]. TGF-1 is thought to be
produced locally by medial and neointimal smooth mus-
cle cells, as well as by macrophages and lymphocytes within
the stenotic lesion of AV fistulas [24]. TGF-1 stimulates
extracellular matrix protein production and inhibits the
degradation of matrix proteins [16]. It has a bimodal ef-
fect on smooth muscle cell proliferation [19]. In addition,
TGF-1 induces the expression of PDGF [26] and fibro-
blast growth factor (FGF) [27]. PDGF and FGF are im-
portant mediators of the smooth muscle cell proliferation
and/or their migration into the intima [28, 29], and of accu-
mulation of extracellular matrix proteins [30], which char-
acterizes neointimal hyperplasia. In accordance, PDGF
and FGF are overexpressed in stenosed AV fistula [6].
In agreement with a prominent role of TGF-1 in AV
fistula stenosis, the injection of TGF-1 was shown to
induce a more pronounced intimal thickening than pla-
cebo in arterial balloon injury, an animal model of intimal
hyperplasia in which histologic changes closely resemble
those found in AV fistula stenosis [31]. Administration
of neutralizing anti-TGF-1 significantly reduces intimal
hyperplasia after arterial balloon injury [32]. We suggest
that our data may further confirm an important role
of TGF-1 in the development of AV fistula stenosis.
Hemodialysis patients who are predisposed to increased
TGF-1 synthesis because of genetic polymorphisms
were found to have a significantly shorter unassisted AV
fistula patency.
It was recently reported that TGF-1 polymorphisms
do not result in different serum levels of TGF-1 in
hemodialysis patients [33]. These data do not contradict
our findings, as overexpression of TGF-1 in stenosed
AV fistula should be regarded as a localized phenome-
non occurring in tissue injury that does not result in a
systemic increase in TGF-1 serum levels. In accordance,
it was recently shown that the local expression of TGF-1
in stenosed AV fistulas does not correlate to TGF-1
serum levels, and that no increase in TGF-1 levels is
found in patients with AV fistula stenosis compared to
uremic controls [24].
Neither older age nor the presence of diabetes mellitus
were significant risk factors for AV fistula failure, which
is in accordance with most recent multicenter [34, 35] and
large single-center [36] studies on AV fistula patency.
Earlier single-center studies, which reported a signifi-
cantly poorer fistula patency in elderly or diabetic pa-
tients, included smaller numbers of patients [37, 38]. In
contrast, diabetes mellitus and/or older age may predis-
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pose to access failure in patients with an AV graft of
synthetic material [35, 39].
In addition, we found that patients with cardiovascular
disease are not prone to earlier fistula failure, which is in
accordance with recent studies reporting no correlation
between failure of native AV fistula and a history of
peripheral vascular disease [40, 41], coronary artery dis-
ease [34, 41], or cerebral vascular disease [34]. Intimal
hyperplasia occurring in AV fistula stenosis, as well as
in restenosis after coronary intervention, histologically
and pathogenetically differs from atherosclerotic lesions,
in which inflammation and endothelial dysfunction play
a more prominent role than in AV fistula stenosis. This
may explain the seeming contradiction as to why a high
production of TGF-1 is detrimental in AV fistula, in
which TGF-1 induces extracellular matrix production,
but is protective in atherosclerotic lesions due to the
immunosuppression and protection of endothelial func-
tion mediated by TGF-1.
CONCLUSION
We suggest that our data may allow identifying pro-
spectively those patients with chronic renal failure who
are prone to early access failure. At present, a prophylac-
tic medication lowering the risk of AV fistula thrombosis
may be offered to these patients [42]. As first clinical
trials on tranilast, which inhibits the release of TGF- and
other cytokines, showed a clinically significant reduction
in restenosis after coronary angioplasty without severe
systemic side effects [43], the selective pharmacologic
blockade of signals for matrix production may be an
attractive, albeit eager, future goal in improving AV
access patency.
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